Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Nov;66(5):981–983. doi: 10.1038/bjc.1992.396

Immunological effects of alternative weekly interferon-alpha-2b and low dose interleukin-2 in patients with cancer.

B Fiorentino 1, P Di Stefano 1, C Giuliani 1, C Amatetti 1, N Tinari 1, C Natoli 1, C Garufi 1, S Iacobelli 1
PMCID: PMC1977987  PMID: 1419647

Full text

PDF
981

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atzpodien J., Kirchner H. Cancer, cytokines, and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasms. Klin Wochenschr. 1990 Jan 4;68(1):1–11. doi: 10.1007/BF01648882. [DOI] [PubMed] [Google Scholar]
  2. Atzpodien J., Körfer A., Franks C. R., Poliwoda H., Kirchner H. Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet. 1990 Jun 23;335(8704):1509–1512. doi: 10.1016/0140-6736(90)93039-r. [DOI] [PubMed] [Google Scholar]
  3. Cameron R. B., McIntosh J. K., Rosenberg S. A. Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases. Cancer Res. 1988 Oct 15;48(20):5810–5817. [PubMed] [Google Scholar]
  4. Faltynek C. R., Oppenheim J. J. Interferons in host defense. J Natl Cancer Inst. 1988 Apr 6;80(3):151–153. doi: 10.1093/jnci/80.3.151. [DOI] [PubMed] [Google Scholar]
  5. Foon K. A. Biological response modifiers: the new immunotherapy. Cancer Res. 1989 Apr 1;49(7):1621–1639. [PubMed] [Google Scholar]
  6. Goldstein D., Sosman J. A., Hank J. A., Weil-Hillman G., Moore K. H., Borchert A., Bechhofer R., Storer B., Kohler P. C., Levitt D. Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activity. Cancer Res. 1989 Dec 1;49(23):6832–6839. [PubMed] [Google Scholar]
  7. Hank J. A., Kohler P. C., Weil-Hillman G., Rosenthal N., Moore K. H., Storer B., Minkoff D., Bradshaw J., Bechhofer R., Sondel P. M. In vivo induction of the lymphokine-activated killer phenomenon: interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin 2. Cancer Res. 1988 Apr 1;48(7):1965–1971. [PubMed] [Google Scholar]
  8. Iigo M., Sakurai M., Tamura T., Saijo N., Hoshi A. In vivo antitumor activity of multiple injections of recombinant interleukin 2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors. Cancer Res. 1988 Jan 15;48(2):260–264. [PubMed] [Google Scholar]
  9. Lee K. H., Talpaz M., Rothberg J. M., Murray J. L., Papadopoulos N., Plager C., Benjamin R., Levitt D., Gutterman J. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A in cancer patients: a phase I study. J Clin Oncol. 1989 Nov;7(11):1726–1732. doi: 10.1200/JCO.1989.7.11.1726. [DOI] [PubMed] [Google Scholar]
  10. Pichert G., Jost L. M., Fierz W., Stahel R. A. Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma. Br J Cancer. 1991 Feb;63(2):287–292. doi: 10.1038/bjc.1991.67. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Rosenberg S. A. Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2. Important Adv Oncol. 1986:55–91. [PubMed] [Google Scholar]
  12. Rosenberg S. A., Lotze M. T., Mulé J. J. NIH conference. New approaches to the immunotherapy of cancer using interleukin-2. Ann Intern Med. 1988 Jun;108(6):853–864. doi: 10.7326/0003-4819-108-6-853. [DOI] [PubMed] [Google Scholar]
  13. Rosenberg S. A., Lotze M. T., Yang J. C., Linehan W. M., Seipp C., Calabro S., Karp S. E., Sherry R. M., Steinberg S., White D. E. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol. 1989 Dec;7(12):1863–1874. doi: 10.1200/JCO.1989.7.12.1863. [DOI] [PubMed] [Google Scholar]
  14. Rosenberg S. A., Schwarz S. L., Spiess P. J. Combination immunotherapy for cancer: synergistic antitumor interactions of interleukin-2, alfa interferon, and tumor-infiltrating lymphocytes. J Natl Cancer Inst. 1988 Nov 2;80(17):1393–1397. doi: 10.1093/jnci/80.17.1393. [DOI] [PubMed] [Google Scholar]
  15. Rosenthal N. S., Hank J. A., Kohler P. C., Minkoff D. Z., Moore K. H., Bechhofer R., Hong R., Storer B., Sondel P. M. The in vitro function of lymphocytes from 25 cancer patients receiving four to seven consecutive days of recombinant IL-2. J Biol Response Mod. 1988 Apr;7(2):123–139. [PubMed] [Google Scholar]
  16. Sondel P. M., Kohler P. C., Hank J. A., Moore K. H., Rosenthal N. S., Sosman J. A., Bechhofer R., Storer B. Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer. Cancer Res. 1988 May 1;48(9):2561–2567. [PubMed] [Google Scholar]
  17. Stein R. C., Malkovska V., Morgan S., Galazka A., Aniszewski C., Roy S. E., Shearer R. J., Marsden R. A., Bevan D., Gordon-Smith E. C. The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin-2 [corrected]. Br J Cancer. 1991 Feb;63(2):275–278. doi: 10.1038/bjc.1991.64. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Urba W. J., Steis R. G., Longo D. L., Kopp W. C., Maluish A. E., Marcon L., Nelson D. L., Stevenson H. C., Clark J. W. Immunomodulatory properties and toxicity of interleukin 2 in patients with cancer. Cancer Res. 1990 Jan 1;50(1):185–192. [PubMed] [Google Scholar]
  19. Whitehead R. P., Ward D., Hemingway L., Hemstreet G. P., 3rd, Bradley E., Konrad M. Subcutaneous recombinant interleukin 2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma. Cancer Res. 1990 Oct 15;50(20):6708–6715. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES